- Home
- PHUN vs FBRX Comparison
PHUN vs FBRX Comparison
Compare PHUN & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- FBRX
- Stock Information
- Founded
- PHUN 2009
- FBRX N/A
- Country
- PHUN United States
- FBRX United States
- Employees
- PHUN N/A
- FBRX N/A
- Industry
- PHUN EDP Services
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- FBRX Health Care
- Exchange
- PHUN Nasdaq
- FBRX Nasdaq
- Market Cap
- PHUN 64.1M
- FBRX 69.7M
- IPO Year
- PHUN N/A
- FBRX N/A
- Fundamental
- Price
- PHUN $3.29
- FBRX $10.55
- Analyst Decision
- PHUN Buy
- FBRX Strong Buy
- Analyst Count
- PHUN 2
- FBRX 2
- Target Price
- PHUN $7.75
- FBRX $61.00
- AVG Volume (30 Days)
- PHUN 280.4K
- FBRX 185.0K
- Earning Date
- PHUN 08-07-2025
- FBRX 08-13-2025
- Dividend Yield
- PHUN N/A
- FBRX N/A
- EPS Growth
- PHUN N/A
- FBRX N/A
- EPS
- PHUN N/A
- FBRX N/A
- Revenue
- PHUN $2,956,000.00
- FBRX N/A
- Revenue This Year
- PHUN $3.01
- FBRX N/A
- Revenue Next Year
- PHUN $50.72
- FBRX N/A
- P/E Ratio
- PHUN N/A
- FBRX N/A
- Revenue Growth
- PHUN N/A
- FBRX N/A
- 52 Week Low
- PHUN $2.22
- FBRX $4.11
- 52 Week High
- PHUN $14.60
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- PHUN 52.92
- FBRX 44.73
- Support Level
- PHUN $3.25
- FBRX $10.15
- Resistance Level
- PHUN $3.56
- FBRX $13.20
- Average True Range (ATR)
- PHUN 0.18
- FBRX 1.89
- MACD
- PHUN 0.01
- FBRX -0.38
- Stochastic Oscillator
- PHUN 61.97
- FBRX 4.72
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).